OUP (Osage University Partners)

What OUP (Osage University Partners) does

OUP (Osage University Partners) is a US-based venture capital firm founded in 2009 that invests exclusively in startups commercializing university research. The firm is headquartered in Bala Cynwyd, Pennsylvania, and operates as OUP Management Co., LLC (Delaware). OUP invests $1-20M per company across all stages from pre-seed through crossover in two sectors: Tech (Software, Hardware, Climate Tech) and Life Science (Therapeutics, Medtech, Diagnostics, Research Tools). The firm manages approximately $800M across its funds and currently invests out of its fourth fund, launched in 2023.

OUP sources its deal flow through formal partnerships with 150+ universities and research institutions in the US and abroad, supported by a proprietary database of active university spinouts and a dedicated Academic Partner Portal that provides TTOs with deal templates, license resources, and networking. The team comprises Managing Partners across sectors (Matt Cohen for Life Sciences, Marc Singer for Tech, Manny Stockman for Tech, Bill Harrington, and Robert Adelson as Managing Partner & President), alongside principals, associates, and finance and IR leadership. In January 2026, OUP launched the $50 million Penn-BioNTech Innovative Therapeutics Seed (PxB) Fund in partnership with the University of Pennsylvania and BioNTech SE, with Anna Turetsky appointed as General Partner, representing an expansion into sponsor-anchored single-institution vehicles.

OUP generates returns through equity investments in university spinouts, realizing upside via IPOs, acquisitions, and secondary sales. The portfolio includes 35+ companies that have achieved successful IPOs, 9 approved medicines, and 11 approved medical products, with highlighted public holdings including IonQ, Beam Therapeutics, Sana Biotechnology, and DICE Therapeutics. The firm's revenue mechanics are typical of the venture model — management fees on committed capital plus carried interest from exits — and the firm does not publicly disclose revenue.

Name

OUP (Osage University Partners)

Legal name

OUP MANAGEMENT CO., LLC

Website

https://oup.vc

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

OUP (Osage University Partners) is a US venture capital firm founded in 2009 that invests $1-20M in pre-seed through crossover rounds of university research spinouts in Tech and Life Sciences, managing approximately $800M across its funds and 150+ portfolio companies.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Education / EdTech Growth Equity (FSANACAL)

akta.pro secondary industries

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH), Technical Universities with Strong Industry Partnerships (EDAHAEAG)

Keywords

• Venture capital investing
• University spinouts
• Deep tech funding
• Life science venture
• Early stage capital

Headquarters

HQ city

Bala Cynwyd

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture Capital Returns: OUP generates returns through equity investments in university spinout startups. The firm invests in breakthrough science and technology companies and realizes returns through IPOs, acquisitions, and secondary sales of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Osage University Partners is a venture capital firm that invests $1-20M in pre-seed through crossover stage startups commercializing research from universities and research labs. The firm manages approximately $800M across multiple funds, focusing on Technology (software, hardware, climate tech) and Life Science (therapeutics, medtech, diagnostics, research tools) sectors. OUP partners with 150+ universities and research institutions to source and support spinout companies.

Product overview

OUP (Osage University Partners) is a venture capital firm specializing in investing in deep technology and life science startups emerging from university research institutions. The firm manages approximately $800M across multiple funds and has invested in 150+ portfolio companies. OUP's services include sourcing investments from university spinouts, providing capital and operational support to founders, and facilitating connections between portfolio companies and strategic partners. The firm invests across two primary sectors: Technology (Software, Hardware, Climate Tech) and Life Science (Therapeutics, Medtech, Diagnostics, Research Tools), typically making initial investments of $1-20M ranging from pre-seed through crossover stages.

Differentiator

Problem solved

Functional benefit

Products and services

• Penn-BioNTech Innovative Therapeutics Seed (PxB) Fund A $50M co-branded seed and Series A investment fund for therapeutics, diagnostics, digital platforms, and research tools emerging from the University of Pennsylvania, managed by Osage University Partners in partnership with BioNTech SE. Targeted at university researchers and spinouts from Penn.
• University Spinout Venture Capital Investment Program OUP's core investment program deploying $1-20M in equity capital into university spinout companies across pre-seed through crossover stages. The firm invests across Technology (software, hardware, climate tech) and Life Science (therapeutics, medtech, diagnostics, research tools) sectors, sourced through a network of 150+ university and research institution partners. The firm manages approximately $800M across its funds.

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• University of PennsylvaniacoreStrategic or Co-development Partner · 20 January 2026OUP manages the $50 million Penn-BioNTech Innovative Therapeutics Seed (PxB) Fund, providing seed and Series A investments to university researchers working on therapeutics, diagnostics, digital platforms, and research tools emerging from Penn.
• BioNTech SEcoreStrategic or Co-development Partner · 20 January 2026BioNTech partnered with University of Pennsylvania and OUP to launch the $50M PxB Fund, aiming to deepen its longstanding R&D partnership with the university and invest in early-stage life science companies.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Lux Capital: Lux is a comparable deep-tech investor that actively backs university spinouts across hard sciences, AI, and life sciences, with a similarly specialized, science-heavy diligence culture targeting founder-researchers.
• Atlas Venture: Atlas is a peer in life sciences, building biotech companies (often from academic science) at the seed/Series A stage with a dedicated team of former scientists and operators, mirroring OUP's Life Science franchise.
• ARCH Venture Partners: ARCH is a direct peer: a deep-tech and life-science venture firm with a long-standing focus on university and national-lab spinouts (e.g., Illumina, BLUEPRINT, Karuna), competing head-to-head with OUP for the same category of research-originated companies.
• Flagship Pioneering: Flagship is a direct peer in life sciences, originating and building biotech companies from breakthrough science (often academic in origin) with a scientist-founder culture similar to OUP's life science team.
• DCVC (Data Collective): DCVC is a peer deep-tech investor focused on computational and science-driven companies emerging from research institutions, overlapping with OUP on AI, climate, and physical-tech investments from academic labs.

Regional players

• Brandon Capital Partners: Brandon Capital is a regional peer that partners with Australian and global research institutions to form and fund biotech spinouts, similar to OUP's university-anchored model but focused on the Australasian ecosystem.

Broad incumbents

• RA Capital Management: RA Capital is a healthcare-focused crossover investor that frequently leads or co-leads rounds OUP participates in (e.g., Terremoto Biosciences), making it both a competitor and a recurring co-investor in life sciences.
• Andreessen Horowitz (a16z Bio): a16z's Bio + General Bio funds compete with OUP for life sciences and tech spinouts (e.g., a16z led Tessera Labs' Series A with OUP participating), and its scale and brand make it a frequent co-investor or competitor.
• Khosla Ventures: Khosla is a broader incumbent that also invests aggressively in university spinouts across tech and life sciences, often at larger check sizes; it competes with OUP for the same founder-researchers and can outbid on price.
• OrbiMed: OrbiMed is a larger healthcare-dedicated investor that competes with OUP's Life Science group for therapeutics, medtech, and diagnostics spinouts from universities and research hospitals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/osage-university-partners
• Instagraminstagram.com/osageuniversitypartners
• Xx.com/OUP_VC
• Facebookfacebook.com/osageuniversitypartners

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments235 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OUP (Osage University Partners)